Rani Therapeutics, a clinical-stage biotech company, has secured $60,300,000 in a recent funding round. The capital injection marks a significant milestone for the company as it advances its innovative platform technology for the oral delivery of biologic drugs. This investment underscores investor confidence in Rani Therapeutics' mission to transform how biologic medicines are administered to patients globally.
The company is focused on addressing the challenge that the vast majority of biologic drugs, critical for millions of patients with chronic conditions, currently require injections. Rani Therapeutics has developed the RaniPill™ technology, a proprietary capsule designed to replace subcutaneous or intravenous injections with an oral pill. The RaniPill™ capsule works by delivering an injection directly to the intestinal wall, a region without sharp pain receptors, and has demonstrated bioavailability comparable to traditional subcutaneous injections.
This latest funding round provides Rani Therapeutics with substantial resources to accelerate the development of its RaniPill™ platform. While specific allocation details were not disclosed, the company plans to deploy the funds towards advancing its clinical programs, expanding research and development efforts, and scaling operational capabilities. The successful close of this funding round is anticipated to bolster Rani Therapeutics' ability to bring its groundbreaking technology closer to market.
Rani Therapeutics believes that oral versions of biologics hold the potential to profoundly improve patient outcomes and quality of life for those who currently rely on chronic self-injections. The company continues its work towards potentially transforming medicine by offering a more convenient and less invasive alternative for administering essential biologic therapies, aiming to expand access and adherence for patients worldwide. This investment positions Rani Therapeutics to further pursue its strategic growth initiatives in the coming years.
